CINRYZE ® (C1 esterase inhibitor [human]) is the first FDA-approved preventive treatment that can start at age 6, helping to reduce HAE attacks earlier in life. Start with HAE attack prevention. Learn how CINRYZE can reduce the frequency and …

CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (6 years of age and older) with Hereditary Angioedema

What is CINRYZE? CINRYZE was the first C1 esterase inhibitor (C1-INH) approved by the FDA to help prevent swelling attacks in children (6 years of age and older), teenagers and adults. Available since 2008, CINRYZE has successfully been used to help reduce the frequency, severity, and length of attacks in adolescent and adult patients.

2018年7月2日 · 日前，美国FDA批准Shire（夏尔）公司旗下Cinryze（C1酯酶抑制剂），用于6岁及以上儿童遗传性血管性水肿（HAE）患者预防疾病发作。 值得一提的是，这也是首款获批的皮下注射型C1酯酶抑制剂（C1-INH）。

2025年2月12日 · Cinryze (complement C1 esterase inhibitor) is used to prevent attacks of angioedema in people with hereditary angioedema (HAE). Cinryze information includes side effects, news and clinical trial results.

2018年6月22日 · cinryze是首个被证明可以帮助预防hae患者肿胀发作的c1-inh。 在欧洲，CINRYZE是首个也是目前唯一获批用于儿童、青少年和成人HAE患者常规预防性治疗的C1-INH疗法。

2024年12月10日 · CINRYZE (Freeze-Dried powder for Reconstitution) is a lyophilized preparation available in a single-dose vial that contains 500 IU human C1 esterase inhibitor. Each vial must be reconstituted ... CINRYZE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product.

2010年8月24日 · In summary, Cinryze provides replacement therapy in those that have deficiency of the protein and thus is a physiologic approach to therapy and hopefully will add significantly to the quality of life in patients that have HAE.

CINRYZE ® (C1 esterase inhibitor [human]) was the first FDA-approved preventive treatment that can start at age 6, helping to reduce HAE attacks earlier in life. CINRYZE has been proven to reduce attack frequency, severity, and the use of acute treatment. 1,2

CINRYZE is used every 3 or 4 days for prevention of hereditary angioedema (HAE) attacks. It's important that you work closely with your healthcare provider to create a preventive therapy regimen that's right for you or your child.